Willkie Advises on $490 Million Sale of JHP Pharmaceuticals

January 21, 2014

Firm represents Warburg Pincus and JHP Pharmaceuticals in sale of JHP to Par Pharmaceutical.

On January 21, it was announced that Par Pharmaceutical Companies, Inc. has entered into a definitive agreement to acquire Willkie client JHP Group Holdings, the parent company of JHP Pharmaceuticals, a leading specialty pharmaceutical company that develops, manufactures and markets branded and generic sterile injectable products, for approximately $490 million. JHP is a portfolio company of private equity firm Warburg Pincus. Willkie advised Warburg Pincus and JHP in the transaction.

Based in New Jersey, JHP has a portfolio consisting of a variety of branded products in therapeutic areas including anesthesiology, gastroenterology, infectious disease and women's health. Par Pharmaceutical, a portfolio company of private equity firm TPG, is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high-barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals.

Willkie also advised Warburg Pincus in its 2012 acquisition of JHP from Morgan Stanley Principal Investments. The current transaction was handled by a multidisciplinary Willkie deal team led by partners Steven Gartner, Robert Langdon and Thomas Mark, and included partners Jeffrey Goldfarb, Hillel Jacobson and Jordan Messinger; special counsel Miriam Bishop and Jonathan Konoff and associates Joashua Deason, Timothy DeKeyser, Amir Ghavi, Evan Goodman, Jacob Kleinman, Mark Myott, Tej Prakash, Ryan Stott and DJ Stauber.